Although response rates with vemurafenib in patients with V600E BRAF-mutated melanoma have been impressive, this inhibitor is associated with a PFS of only 5-7 months, likely due to the development of compensatory mechanisms of resistance described below [148],[149]. Here, BRAF is linked to melanoma.